The Invesco Growth and Income Fund outperformed its benchmark in Q4 2025, led by industrials and health care. Read the full analysis for more details.
Zacks Investment Research on MSN
IOVA vs. RIGL: Which small-cap biotech has more upside potential?
Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results